Treatment of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus Patient With Local Pulmonary Administration of Factor VIIa (rFVIIa)
| Autor: | Iehab B. Alabed |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Lung Diseases medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Hemorrhage Factor VIIa Article immune system diseases medicine Humans Lupus Erythematosus Systemic skin and connective tissue diseases Adverse effect Lupus erythematosus business.industry Mortality rate Standard treatment Diffuse alveolar hemorrhage General Medicine medicine.disease Recombinant Proteins Surgery Pulmonary Alveoli Bronchoscopes Female Plasmapheresis Complication business medicine.drug |
| Zdroj: | Medicine |
| ISSN: | 0025-7974 |
| DOI: | 10.1097/md.0000000000000072 |
| Popis: | Diffuse alveolar hemorrhage (DAH) is a rare serious life-threatening complication in systemic lupus erythematosus (SLE) associated with a high mortality rate. The old standard treatment options include high-dose corticosteroids, cyclophosphamide, and plasmapheresis, which are unspecific, treating the underlying disease rather than the complication itself, and not effective. We report a case of DAH complicating SLE flare-up in a female patient treated with recombinant activated factor VII (rFVIIa) administered via the bronchoscope that showed clinical and radiological improvement. No toxicity or adverse events were observed with rFVII treatment. rFVII may be an effective treatment option for DAH in SLE patient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|